🇯🇵 日本語 🇺🇸 English
3,791 companies 2,399 AI summaries 1,857 risk analyses 1,326 growth scores Register free — watchlist & alerts →
EDINET 4506 Positive Risk Analyzed 📈 Growth 7/10

Sumitomo Pharma Co.,Ltd.

Annual Securities Report - 206th Term(2025/04/01 - 2026/03/31) ／ 2026-06-23 10:27

Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).

EarningsDividend CutVolumeNew ProductNew MarketDemand
AI Summary 2026-06-23 10:31

FY2026 delivered strong earnings: Revenue +13.7% to ¥453.3B, Operating profit +272.6% to ¥107.3B. North American flagship products (Orgovyx, Gemtesa) drove growth with milestone revenue. Amshepri, world's first iPSC-derived product, approved in Japan. FY2027 guidance cautious due to US pricing/tariff uncertainty.

KEY POINTS
  • Major earnings turnaround driven by North American core products and sales milestones
  • World-first approval of iPSC-derived dopaminergic neural progenitor cells (Amshepri) for Parkinson's disease in Japan
  • FY2027 dividend policy suspended (interim and year-end) citing US policy uncertainty and tariff risk
📊 Revenue
Revenue +13.7% (¥398.8B → ¥453.3B)
💰 Operating profit
OP +272.6% (¥28.8B → ¥107.3B)
🔮 Outlook
FY2027 Core OP forecast ¥91.0B (subject to Orgovyx milestone receipt). Dividend payments to be determined based on business performance.
📈 Growth outlook 📈 Growth 7/10
North American revenue growth is primary driver. World-first iPSC product launch and robust R&D pipeline offer medium-term opportunities in regenerative medicine. US market uncertainty and competitive pressures on core products present downside risks.
Growth drivers
  • North American flagship product sales expansion (Orgovyx, Gemtesa) and milestone achievements
  • Market authorization of Amshepri, world's first iPSC-derived therapeutic product, in Japan
  • Advancement of cancer pipeline programs (enzomenib, nuvisertib) driving next-generation revenue base
  • Diversification of Japan business through distribution partnerships (Zyprexa, Ozempic, Wegovy)
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
CategoryDescriptionScoreNew
Market Risk North American core products (Orgovyx, Gemtesa) account for 55% of revenue. Significant sales decline risk from competing products or supply chain disruption. 8/10
Regulatory Risk US drug pricing regulations and tariff policy changes increasing healthcare costs and margin pressure. Explicitly flagged as uncertainty factor in FY2027 guidance. 7/10
Technology Risk High development difficulty for priority cancer programs (enzomenib, nuvisertib). Clinical trial failure risk amid intense competitive landscape in oncology. 7/10
Credit Risk Interest-bearing debt of ¥305.4B vs. equity of ¥169.5B creates high leverage. Rising interest rates in adverse funding environment pose refinancing risk. 6/10
M&A Risk FY2025 Asia business divestiture and ¥4.2B intangible asset impairment demonstrate M&A integration risks. Future acquisitions carry similar realization risk. 6/10
Impairment Risk Goodwill and intangible assets subject to impairment testing. Significant loss risk if future cash flow assumptions change due to development failures or market shifts. 6/10
Supply Chain Risk Manufacturing and supplier disruption from disasters, pandemics, or cyber attacks could interrupt critical drug supply. Stable supply is operational priority. 6/10
Litigation Risk Patent litigation, product liability, and adverse event claims could materially impact financial results. US generic ANDA litigation risk particularly relevant. 5/10
8/10 Market Risk
North American core products (Orgovyx, Gemtesa) account for 55% of revenue. Significant sales decline risk from competing products or supply chain disruption.
7/10 Regulatory Risk
US drug pricing regulations and tariff policy changes increasing healthcare costs and margin pressure. Explicitly flagged as uncertainty factor in FY2027 guidance.
7/10 Technology Risk
High development difficulty for priority cancer programs (enzomenib, nuvisertib). Clinical trial failure risk amid intense competitive landscape in oncology.
6/10 Credit Risk
Interest-bearing debt of ¥305.4B vs. equity of ¥169.5B creates high leverage. Rising interest rates in adverse funding environment pose refinancing risk.
6/10 M&A Risk
FY2025 Asia business divestiture and ¥4.2B intangible asset impairment demonstrate M&A integration risks. Future acquisitions carry similar realization risk.
6/10 Impairment Risk
Goodwill and intangible assets subject to impairment testing. Significant loss risk if future cash flow assumptions change due to development failures or market shifts.
6/10 Supply Chain Risk
Manufacturing and supplier disruption from disasters, pandemics, or cyber attacks could interrupt critical drug supply. Stable supply is operational priority.
5/10 Litigation Risk
Patent litigation, product liability, and adverse event claims could materially impact financial results. US generic ANDA litigation risk particularly relevant.
X LinkedIn Threads Bluesky Facebook
Track Japanese disclosures with JSIGNAL

AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.

Start free — 30-day trial Login